Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis have?

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis has 162 citations in the OpenAlex counts ScholarIQ stores.

When was Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis published?

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis has 2010 year in the ScholarIQ index.

What is the open-access status of Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis?

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis has closed oa status in the ScholarIQ index.

What is the DOI of Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis?

The DOI for Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis is on the source record.

What is the PMID of Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis?

The PMID for Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis is on the source record.

What is the OpenAlex record for Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis?

The OpenAlex for Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis is on the source record.